Pulmonary Fibrosis Foundation to Fund Further Therapeutic Evaluation Studies for Compugen Ltd. (CGEN)-Discovered Drug Candidate  
10/12/2011 9:30:38 AM

TEL AVIV, Israel & CHICAGO--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) and the Pulmonary Fibrosis Foundation announced today that the Pulmonary Fibrosis Foundation will provide a grant to scientists at the University of Pittsburgh Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease to independently evaluate the therapeutic potential of CGEN-25009 for the treatment of idiopathic pulmonary fibrosis (IPF), a devastating disease with no current effective treatment and which is estimated to affect more than five million people worldwide.